Nexalin Technology’s HALO Clarity headset approved for use in trials by UCSD

Nexalin Technology (NXL) has received Institutional Review Board – IRB – approval from the University of California, San Diego, or UCSD, for clinical testing of its HALO Clarity headset in human subjects. This study is being conducted independently by UCSD. Nexalin is providing the HALO devices for research purposes but is not sponsoring, directing, or controlling the study or its outcomes. This approval follows a successful pilot testing protocol conducted with UCSD’s research team. With this milestone achieved, UCSD has requested and will receive 50 HALO devices from Nexalin for this independent research project. Nexalin and its manufacturing partner have begun preparing the initial shipment of 50 HALO devices to UCSD. The HALO Clarity is powered by Nexalin’s proprietary Deep Intracranial Frequency Stimulation technology. The HALO device is currently under evaluation and not yet approved by the FDA for these uses in the U.S.